Posts

Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB 2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.

/by

Authors: Magdalena Florek-Luszczki, Aleksandra Wlaz, Maria W. Kondrat-Wrobel, et al
Journal of Neural Transmission, July 2014
—
The aim of this study was to characterize the influence of WIN 55,212-2 (WIN–a non-selective cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant effects of various classical antiepileptic drugs (clobazam, clonazepam, phenobarbital and valproate) in the mouse 6 Hz-…

Read more

The case for medical marijuana in epilepsy.

/by

Authors: Edward Maa, Paige Figi
Epilepsia, June 2014
—
Charlotte, a little girl with SCN1A-confirmed Dravet syndrome, was recently featured in a special that aired on CNN. Through exhaustive personal research and assistance from a Colorado-based medical marijuana group (Realm of Caring), Charlotte’s mother started adjunctive thera…

Read more

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

/by

Authors: Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez‐Ruiz, et al
Epilepsia, June 2014
—
To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant…

Read more

The case for assessing cannabidiol in epilepsy

/by

Authors: Maria Roberta Cilio, Elizabeth A. Thiele, Orrin Devinsky
Epilepsia, June 2014
—
Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the ma…

Read more

Cannabinoids for epilepsy.

/by

Authors: David Gloss, Barbara Vickrey
Cochrane Database of Systematic Reviews, 5 March 2014
—
BACKGROUND: Marijuana appears to have anti-epileptic effects in animals. It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly approved its use for epilepsy. OBJECTIVES: To assess the efficacy and sa…

Read more

The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.

/by

Authors: Melisa J. Wallace, Robert E. Blair, Katherine W. Falenski, Billy R. Martin, Robert J. DeLorenzo
Journal of Pharmacology and Experimental Therapeutics, October 2003
—
Several lines of evidence suggest that cannabinoid compounds are anticonvulsant. However, the anticonvulsant potential of cannabinoids and, moreover, the role of the endogenous cannabinoid system in regulating seizure activity has not been tested in an in vivo model of epileps…

Read more

Hypnotic and antiepileptic effects of cannabidiol.

/by

Authors: Elisaldo A. Carlini, Jomar M. Cunha
The Journal of Clinical Pharmacology, August-September 1981
—
Clinical trials with cannabidiol (CBD) in healthy volunteers, isomniacs, and epileptic patients conducted in the authors’ laboratory from 1972 up to the present are reviewed. Acute doses of cannabidiol ranging from 10 to 600 mg and chronic administration of 10 mg for 20 days o…

Read more

Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats.

/by

Authors: Juhn A. Wada, Akira Wake, Mitsumoto Sato, Michael E. Corcoran
Epilepsia, September 1975
—
Acute administration of delta8-tetrahydrocannabinol (delta8-THC) or delta9-THC failed to affect partially developed or fully developed kindled amygdaloid seizures in cats. However, delta9-THC was quite effective in suppressing focal AD in the stimulated amygdala when administe…

Read more